<DOC>
	<DOCNO>NCT00401804</DOCNO>
	<brief_summary>The primary objective study evaluate activity BDD subject acute renal failure measure by· reversal acute renal failureSecondary objectives· tumor response ( complete partial response ) · To evaluate safety Bortezomib- Doxorubicin-Dexamethasone patient population· evaluate activity Bortezomib- Doxorubicin -Dexamethasone progression free survival · evaluate activity Bortezomib- Doxorubicin -Dexamethasone overall survival</brief_summary>
	<brief_title>Bortezomib-Dexamethasone-Doxorubicin-Study</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Confirmed diagnosis multiple myeloma · Acute multiple myeloma relate renal failure ( Diagnosis establish clinical laboratory finding include renal biopsy indicate ) ) Newly diagnose patient : Decrease GFR &lt; 50ml/minb ) Previously treat patient GFR ≥ 60ml/min within last 4 week : decrease GFR &gt; 25 % &lt; 60ml / min , concomitantly either increase paraproteins ( &gt; 25 % ) and/or decrease hemoglobin ≥ 2 g/dl ( within 4 week ) and/or increase bone marrow plasma infiltration and/or increase number bone lesion and/or hypercalcaemia ( Ca &gt; 11.5 mg/dl 2.8 mmol/l ) sign disease progression· Age &gt; 20 years· ECOG performance status ≤ 3.· Platelet count &gt; 50.000/µl· WBC &gt; 2000/µl· Total bilirubin &lt; 1.5 x upper limit normal , AST , ALT &lt; 2.5 x upper limit normal· International Normalized Ratio ( INR ) &lt; 1.5 ; APTT &lt; 1.5 x upper limit normal· Fertile woman men childbearing potential ( &lt; 2 year last menstruation woman ) must use effective mean contraception ( oral contraceptive , intrauterine contraceptive device , barrier method contraception conjunction spermicidal jelly surgically sterile ) · Negative serum urine βHCG pregnancy test screen subject childbearing potential· Patient 's write informed consent History malignancy squamous cell carcinoma , basal cell carcinoma skin carcinoma situ cervix within last 5 years.· Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study treatment start , anticipation need major surgical procedure course study.· Evidence CNS involvement spinal cord compression.· Neuropathy Grade ≥ 2· A history uncontrolled seizure , central nervous system disorder psychiatric disability judge investigator clinically significant adversely affect compliance study drug.· NYHA Status &gt; 2 , i.e . clinically significant cardiac disease , ( congestive heart failure , symptomatic coronary artery disease , cardiac arrhythmia , arterial hypertension well control medication ) myocardial infarction within last 6 month · Evidence bleed diathesis coagulopathy· Serious , nonhealing wound ulcer· Evidence severe active acute chronic infection.· Evidence disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug patient high risk treatment complications· Patient know HIVpositive , Hbsantigen positive HCVRNApositive· Pregnant woman nurse mothers· Have receive bortezomib within 4 week enrollment· Half body irradiation &lt; 28 day enrollment· Has know suspect hypersensitivity intolerance boron , mannitol , heparin , indwell catheter use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>renal impairment</keyword>
	<keyword>Velcade</keyword>
</DOC>